The company, based in Norcross, GA, manufactures more than 900 DNA and RNA isolation products used in clinical research, biotechnology, genomics, and agriculture.

Eli Lilly will shell out $2.4 billion to acquire genetic medicine developer Orna Therapeutics and has committed up to $8.85 billion to launch a seventh collaboration with Innovent Biologics. Both ...

A new study has found bacterial sugars that cause neurodegenerative immune response, providing a mechanism for therapeutic intervention.

"Successful automation depends on orchestration, not just robotics," notes Werner Maas, PhD, CEO, Hudson Lab Automation.

In this GEN webinar, Joshua Orchard, a purification applications scientist with extensive experience in downstream process development of various modalities, will share strategies and experimental ...

The goal of the partnership is to develop synthetic datasets to train vision language action models on various experimental workflows ...

Active Genetics (Pro-AG) exploits a naturally created bacterial mating tunnel between cells to inactivate antibiotic resistance.

Preclinical results indicate new approach could be a way to deliver treatment directly to tumors at higher doses, while reducing side effects in healthy tissue.

Researchers elucidated the connection between influenza infection and cardiac disease in mammals by studying human and mouse hearts.

Takeda Pharmaceutical will apply Iambic Therapeutics’ artificial intelligence (AI)-based technologies and wet lab capabilities to design and develop small molecule drugs through a multi-year tech and ...

In a study using gut microbiome samples from over 11,000 people across 39 countries, a single group of bacteria (CAG-170) has been found in higher numbers in the gut microbiomes of healthy people. CAG ...

Bristol Myers Squibb (NYSE: BMY; BMS) beat analyst consensus forecasts by reporting higher than expected numbers for total revenue and its “growth” portfolio of drugs on which BMS is counting on for ...